论文部分内容阅读
目的了解乙肝病毒(HBV)B、C基因型与拉米夫定抗HBV的关系。方法采用前瞻性和回顾性相结合的方法收集资料,患者口服拉米夫定100 mg/d治疗至少12个月,停药观察至少6个月。采用多引物对巢式PCR法检测HBV基因型。结果共收集并检测出C基因型24例,B基因型22例。B、C基因型患者的病毒学应答在服药6个月、服药12个月及停药时无统计学意义,停药6个月后的病毒学应答有统计学意义,B基因型优于C基因型。结论B基因型患者停药6个月后的持续病毒学应答优于C基因型。
Objective To investigate the relationship between hepatitis B virus (HBV) B and C genotype and anti-HBV lamivudine. Methods The data were collected by prospective and retrospective methods. Patients were treated with lamivudine 100 mg / d orally for at least 12 months and discontinued for at least 6 months. Multiple primers were used to detect HBV genotypes by nested PCR. Results A total of 24 C genotypes and 22 B genotypes were collected and detected. The virological responses of patients with genotype B and C were not statistically significant at 6 months, 12 months and 12 months after drug withdrawal. The virological response after 6 months withdrawal was statistically significant, and the genotype B was superior to C genotype. Conclusions The sustained virological response of patients with genotype B after six months withdrawal is superior to genotype C.